BR112022015380A2 - Composições e métodos para edição de gene de calicreína (klkb1) - Google Patents

Composições e métodos para edição de gene de calicreína (klkb1)

Info

Publication number
BR112022015380A2
BR112022015380A2 BR112022015380A BR112022015380A BR112022015380A2 BR 112022015380 A2 BR112022015380 A2 BR 112022015380A2 BR 112022015380 A BR112022015380 A BR 112022015380A BR 112022015380 A BR112022015380 A BR 112022015380A BR 112022015380 A2 BR112022015380 A2 BR 112022015380A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
klkb1
gene
kallykrein
Prior art date
Application number
BR112022015380A
Other languages
English (en)
Inventor
Odate Shobu
Lynn Seitzer Jessica
Original Assignee
Intellia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intellia Therapeutics Inc filed Critical Intellia Therapeutics Inc
Publication of BR112022015380A2 publication Critical patent/BR112022015380A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fodder In General (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIÇÕES E MÉTODOS PARA EDIÇÃO DE GENE DE CALICREÍNA (KLKB1). Composições e métodos para editar, por exemplo, introduzir quebras de fita dupla, dentro do gene KLKB1 são fornecidos. Composições e métodos para tratar indivíduos tendo angioedema hereditário (HAE) são fornecidos.
BR112022015380A 2020-02-07 2021-02-05 Composições e métodos para edição de gene de calicreína (klkb1) BR112022015380A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062971906P 2020-02-07 2020-02-07
US202062981965P 2020-02-26 2020-02-26
US202063019076P 2020-05-01 2020-05-01
PCT/US2021/016730 WO2021158858A1 (en) 2020-02-07 2021-02-05 Compositions and methods for kallikrein ( klkb1) gene editing

Publications (1)

Publication Number Publication Date
BR112022015380A2 true BR112022015380A2 (pt) 2022-09-27

Family

ID=74873798

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015380A BR112022015380A2 (pt) 2020-02-07 2021-02-05 Composições e métodos para edição de gene de calicreína (klkb1)

Country Status (14)

Country Link
US (2) US20230295587A1 (pt)
EP (1) EP4100528A1 (pt)
JP (1) JP2023512758A (pt)
KR (1) KR20220139352A (pt)
CN (1) CN115362256A (pt)
AU (1) AU2021216451A1 (pt)
BR (1) BR112022015380A2 (pt)
CA (1) CA3169813A1 (pt)
CL (1) CL2022002095A1 (pt)
CO (1) CO2022012196A2 (pt)
IL (1) IL295280A (pt)
MX (1) MX2022009658A (pt)
TW (1) TW202146030A (pt)
WO (1) WO2021158858A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230158059A1 (en) * 2021-10-01 2023-05-25 Adarx Pharmaceuticals, Inc. Prekallikrein-modulating compositions and methods of use thereof
WO2023086953A1 (en) * 2021-11-11 2023-05-19 Beam Therapeutics Inc. Compositions and methods for the treatment of hereditary angioedema (hae)
TW202346586A (zh) * 2022-01-28 2023-12-01 大陸商上海舶望製藥有限公司 用於抑制前激肽釋放酶（pkk）蛋白表達的組合物和方法
TW202405169A (zh) * 2022-07-08 2024-02-01 美商英特利亞醫療公司 活體內編輯ｋｌｋｂ１之方法
WO2024012435A1 (en) * 2022-07-11 2024-01-18 CorrectSequence Therapeutics Co., Ltd Gene editing systems and methods for treating hereditary angioedema

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3320922A1 (en) * 2011-06-10 2018-05-16 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
EP3715457A3 (en) * 2013-08-28 2020-12-16 Ionis Pharmaceuticals, Inc. Modulation of prekallikrein (pkk) expression
ES2774968T3 (es) * 2013-12-19 2020-07-23 Novartis Ag Lípidos y composiciones lipídicas para la administración de agentes activos
EP3862362A3 (en) * 2014-05-01 2021-10-27 Ionis Pharmaceuticals, Inc. Conjugates of modified antisense oligonucleotides and their use for modulating pkk expression
TW202336231A (zh) * 2015-05-06 2023-09-16 美商阿尼拉製藥公司 第十二因子（哈格曼因子）（Ｆ１２）、激肽釋放素Ｂ、血漿（夫列契因子）１（ＫＬＫＢ１）及激肽原１（ＫＮＧ１）ｉＲＮＡ組成物及其使用方法
WO2019010342A1 (en) * 2017-07-07 2019-01-10 Alnylam Pharmaceuticals, Inc. METHODS OF TREATING OR PREVENTING DISEASES ASSOCIATED WITH THE CONTACT ACTIVATION PATHWAY USING FIBER XII-TARGETING RNAI COMPOSITIONS (FACTOR HAGEMAN) (F12)
EP4054651A1 (en) * 2019-11-08 2022-09-14 Regeneron Pharmaceuticals, Inc. Crispr and aav strategies for x-linked juvenile retinoschisis therapy

Also Published As

Publication number Publication date
MX2022009658A (es) 2022-10-27
US20230295587A1 (en) 2023-09-21
TW202146030A (zh) 2021-12-16
AU2021216451A1 (en) 2022-09-29
JP2023512758A (ja) 2023-03-29
EP4100528A1 (en) 2022-12-14
CL2022002095A1 (es) 2023-03-10
US20240018496A1 (en) 2024-01-18
IL295280A (en) 2022-10-01
CO2022012196A2 (es) 2022-09-09
CA3169813A1 (en) 2021-08-12
WO2021158858A1 (en) 2021-08-12
CN115362256A (zh) 2022-11-18
KR20220139352A (ko) 2022-10-14

Similar Documents

Publication Publication Date Title
BR112022015380A2 (pt) Composições e métodos para edição de gene de calicreína (klkb1)
PH12020551923A1 (en) Methods and compositions for treating cancer
CO2021005231A2 (es) Composiciones y métodos para la edición génica de lactato deshidrogenasa (ldha)
BR112018003985A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112021019196A2 (pt) Composições e métodos compreendendo um rna guia de ttr e um polinucleotídeo codificando um agente de ligação de dna guiado por rna
BRPI0517887A (pt) combinações de inibidores de jaks
MX2020003608A (es) Composiciones y métodos para la edición del gen ttr y el tratamiento de la amiloidosis attr.
BRPI0517238A (pt) formulações que compreendem ecteinascidina e um dissacarìdeo
BRPI0416268A (pt) composições de delta-9-thc e métodos para o tratamento de sintomas associados à esclerose múltipla
BR112018000399A2 (pt) método para preparar um produto polimérico, produto polimérico, produto polimérico para cultivar células ou tecidos e solução de revestimento polimérico
BR112019007210A2 (pt) métodos e composições para o tratamento da doença de fabry
CL2008001057A1 (es) Agente para el tratamiento de micosis producida por saprolegnia, achlya y/o aphanomyces en peces, el cual comprende al menos un fungicida seleccionado entre a) inhibidores de l a mitosis y division celular, b) inhiidores de la sintesis de ergosterol o, c) derivados de piridina, benzopiranona, carbonitrilo,quinolinas, entre otras.
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
BR112019022280A2 (pt) tratamento de cânceres de her2 positivo
CO2021002691A2 (es) Composiciones y métodos para editar el gen hidroxiácido oxidasa 1 (hao1) para tratar la hiperoxaluria primaria tipo 1 (ph1)
MX2023002233A (es) Compuestos fosfolipidos y usos de estos.
CO2020015377A2 (es) Moduladores de la expresión de apol1
BR112022012867A2 (pt) Tratamento de câncer com inibidores de cdk12/13
TW200507840A (en) Method of treating multiple myeloma
BR112022006476A2 (pt) Oligonucleotídeos com análogos de nucleosídeos
BR112023018948A2 (pt) Edição multiplex com enzimas cas
BR112018072664A2 (pt) composições e métodos para tratamento de inflamação e infecção do olho
CL2021000107A1 (es) Métodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma
EP4295903A3 (en) Compositions and methods for treating farber disease
BR112018001053A2 (pt) compostos, composição farmacêutica e método para inibir, prevenir ou tratar um câncer em um indivíduo